Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
破譯代碼：了解kymera therapeutics的分析師評論
Ratings for Kymera Therapeutics (NASDAQ:KYMR) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中，有5位分析師爲kymera therapeutics (納斯達克:KYMR) 提供了評級，呈現出看好和看淡的觀點混合。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Kymera Therapeutics, presenting an average target of $48.6, a high estimate of $53.00, and a low estimate of $46.00. Witnessing a positive shift, the current average has risen by 1.78% from the previous average price target of $47.75.
在對12個月價格目標的評估中，分析師爲kymera therapeutics揭示了深入的見解，提出了平均目標價爲48.6美元，最高估價爲53.00美元，最低估價爲46.00美元。現在的平均值較之前的平均目標價格47.75美元上升了1.78%，顯示出了積極的走勢。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
In examining recent analyst actions...
通過審查近...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。